[Anti-gastric cancer effects of Z Ajoene and its molecular mechanisms]

Insights

Z Ajoene effectively inhibits gastric cancer cell proliferation and induces apoptosis. This compound also suppresses tumor growth and prolongs survival in animal models by regulating key molecular pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Gastric cancer remains a significant global health challenge with limited effective therapeutic options.
  • Understanding the molecular mechanisms underlying gastric cancer progression is crucial for developing novel treatments.

Purpose of the Study:

  • To investigate the anti-cancer effects of Z Ajoene on MGC-803 gastric cancer cells.
  • To elucidate the molecular mechanisms by which Z Ajoene exerts its therapeutic effects.

Main Methods:

  • In vitro studies involved treating MGC-803 cells with varying concentrations of Z Ajoene and assessing proliferation, mitochondrial membrane potential, nuclear morphology, cytotoxicity, apoptosis, and cell cycle progression.
  • Gene and protein expression levels of key signaling molecules (p53, Caspase-3, RAS, ERK, BCL-2, AKT, mTOR, PI3K) were analyzed using RT-qPCR and Western blot.
  • In vivo studies utilized a gastric cancer xenograft mouse model to evaluate the effects of Z Ajoene on tumor growth and animal survival.

Main Results:

  • Z Ajoene significantly inhibited MGC-803 cell proliferation and increased apoptosis (P<0.01).
  • The expression of p53, Caspase-3, and BAX was upregulated, while RAS, ERK1, BCL-2, AKT, mTOR, and PI3K were downregulated (P<0.01).
  • In vivo, Z Ajoene treatment suppressed tumor growth and significantly prolonged the survival of tumor-bearing mice (P<0.01).

Conclusions:

  • Z Ajoene demonstrates significant therapeutic potential for gastric cancer.
  • It inhibits cancer cell proliferation and induces apoptosis by modulating the PI3K-AKT-mTOR and RAS-RAF-MEK-ERK signaling pathways.

Related Concept Videos

Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
682
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
611
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.0K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
163
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.1K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
779